|
Status |
Public on Jun 09, 2018 |
Title |
Menin-MLL inhibitors block oncogenic transformation by MLL fusion proteins in a fusion partner independent manner |
Organism |
Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
Chromosomal rearrangements of the Mixed Lineage Leukemia (MLL) gene result in fusion proteins which retain the N-terminal portion of MLL fused with one of more than 70 different fusion partners. The high diversity of MLL fusion partners raises a question whether it is possible to develop a general therapeutic strategy to block the oncogenic activity of MLL fusion proteins in a fusion partner independent manner. We have demonstrated that blocking the menin-MLL interaction using small molecule inhibitor inhibits oncogenic activity of different MLL fusion proteins according to a mechanism that is independent on the fusion partner.
|
|
|
Overall design |
MLL-AF9, MLL-AF6 and MLL-AF1P transformed cells were treated with the menin-MLL inhibitor MI-2-2
|
|
|
Contributor(s) |
Grembecka J, Cierpicki T, Purohit T, Wang J |
Citation(s) |
26084867 |
|
Submission date |
Jun 10, 2015 |
Last update date |
Apr 14, 2022 |
Contact name |
Jingya Wang |
E-mail(s) |
wangjin@medimmune.com
|
Phone |
3013980977
|
Organization name |
MedImmune.LLC
|
Street address |
1 Medimmune Way
|
City |
Gaithersburg |
State/province |
Maryland |
ZIP/Postal code |
20878 |
Country |
USA |
|
|
Platforms (1) |
GPL13112 |
Illumina HiSeq 2000 (Mus musculus) |
|
Samples (18)
|
|
Relations |
BioProject |
PRJNA286308 |
SRA |
SRP059329 |